European Expansion Diabeloop has CE marking for DBLG2 and has launched across multiple European markets including Germany, Italy, Spain, Switzerland, the Netherlands, and France, creating channel and co-selling opportunities with hospitals, clinics, and regional distributors for AID systems and integrated CGMs.

US Market Entry With FDA clearance for interoperability and a collaboration with Sequel Med Tech to bring DBLG2 into the United States, there is a clear path to partnerships with U.S. diabetes care networks, DME providers, and payers to accelerate adoption.

Interoperable Platform DBLG2’s integration with Dexcom G7 and other partners like Dana-i and Sequel demonstrates a flexible, interoperable AID ecosystem that is attractive to device manufacturers and clinics seeking scalable automation.

Strategic Partnerships Ongoing alliances with Dexcom, Kaleido, Sequel Med Tech, and Dana-i suggest opportunities for co-marketing, licensing, or white-label collaboration to expand reach in Europe and beyond.

Growth Readiness As a small, well-funded player with recent product launches, there are opportunities to engage mid-market distributors, larger diabetes care players, or investors for distribution deals, co-development, or strategic investments to scale faster.